Connect with us

News

First living tissue 3D printed in space aboard International Space Station

Published

on

Using the “Organaut”, a 3D bioprinter designed for microgravity, Russia has become the first country to print living tissue in space. After a December 3rd cargo delivery to the International Space Station (ISS), cosmonaut Oleg Kononenko completed an experiment with the machine in the Russian sector of the station, successfully producing human cartilage tissue and a rodent thyroid gland. The Organaut was designed via a collaboration with the printer’s maker, 3D Bioprinting Solutions, and Russia’s national space agency, Roscosmos. The United States also has its own bioprinting mission scheduled for the first half of 2019, joining in the march to develop biological solutions for problems that space is well suited to solve.

A 3D bioprinter operates by creating one layer at a time of specified tissue or stem cell material arranged as needed to grow and form as biologically programmed to do. As summarized by Aryeh Batt, the CEO of Precise Bio, a company dedicated to 3D printed bioproducts for human eyes, “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.” In the case of Organaut, an internal robotic mechanism drips living cell fabric layers from an automatic syringe. When living tissue is bioprinted under Earth’s gravity, the artificial cells grow in a flatter structure than their natural state in the human body. In microgravity, however, they form a shape closer to their normal dimensions.

Along with demonstrating the growth advantages of microgravity, Organaut’s tissue samples will provide the ability to study the effect of radiation on the body. “We will look at how the constructs came together, and how they behaved,” confirmed Usef Hesuani, head of laboratory projects and a managing partner of 3D Bioprinting Solutions in a recent press conference. The original Organaut printer was aboard the Soyuz MS-10 spacecraft which experienced an launch failure on October 11, 2018, forcing the U.S. and Russian crew to make an emergency landing. A second one was quickly put together for the subsequent mission.

The Organaut bioprinter, designed to print biological material in zero gravity conditions. | Credit: 3D Bioprinting Solutions

The parent company of 3D Bioprinting Solutions is INVITRO, the largest private medical company in Russia. Founded in 1995 by Aleksandr Ostrovsky, it has 8 laboratories and over 1000 medical offices in eastern Europe, but is primarily based in Skolkovo, a high technology business area in Moscow. Bioprinting Solutions made headlines in 2015 when it printed and transplanted a functioning mouse thyroid gland. The experiment performed aboard the ISS with Organaut was a modified version of their prior work.

Unlike NASA, Roscosmos does not generally partner with private companies for its research endeavors. In an effort to inspire Russian students to enter STEM fields within their country, the agency sought to spotlight the developing bioprinting industry by using the Organaut. The successful partnership with 3D Bioprinting Solutions has now motivated the agency to continue partnering with private companies in the future. The company itself also sees advantages to collaborations of its own with other Skolkova-area manufacturers. “We have companies that are making satellite platforms…it is possible to conduct a similar experiment amid microgravity on small spacecraft [like satellites]…smaller and cheaper,” noted Ivan Kosenkov, 3D Bioprinting Solutions’ project manager.

Advertisement

Organaut’s printed tissues were returned to Earth with the Soyuz MS-09 spacecraft on December 20th, and the results of the experiment are expected to be published at the end of January 2019. In February, NASA plans to send a bioprinter capable of producing beating heart tissue to the ISS. Named the 3D BioFabrication Facility (BFF), the machine was developed through a partnership with two companies well-established in 3D printing and on-orbit hardware, nScrypt and Techshot. Since the thickness of heart tissue is difficult to build under gravity without structural assistance that could impede functionality, the companies developed the BFF with the hypothesis that microgravity would overcome this limitation. Thus far, the concept has been proven during parabolic flight tests, i.e., aboard the “Vomit Comet” airplane that performs multiple parabolic maneuvers in an airliner to create 20-30 seconds of weightlessness each.

Accidental computer geek, fascinated by most history and the multiplanetary future on its way. Quite keen on the democratization of space. | It's pronounced day-sha, but I answer to almost any variation thereof.

Advertisement
Comments

Elon Musk

Ford CEO Farley says Tesla is not who to look at for EV expertise

Interestingly, Farley has been one of the most hellbent CEOs in terms of a legacy automaker standpoint to push the EV effort. It did not go according to plan, as Ford took a $19.5 billion charge and retreated from its EV push in late 2025.

Published

on

elon-musk-jim-farley-tesla-ford

Ford CEO Jim Farley said in a recent podcast interview that Tesla is not who Americans should look at to beat Chinese carmakers.

The comments have sparked quite a bit of outrage from Tesla fans on X, the social media platform owned by Elon Musk.

Farley said that Chinese automakers are better examples of how to beat competitors. He said (via the Rapid Response Podcast):

“If you’re an American and you want us to beat the Chinese in the car business, you’re all going to want to pay attention, not necessarily to Tesla. Nothing against Tesla—they’ve been doing great—but they really don’t have an updated vehicle. The best in the business for us, cost-wise and competition-wise, supply chain, manufacturing expertise, and the I.P. in the vehicle, was really BYD. In this next cycle of EV customers in the U.S., they want pickups and utilities and all these different body styles. But they want them at $30,000, not $50,000. Like the first inning, they want them affordably.”

Advertisement

Despite Farley’s synopsis, it is worth mentioning that Tesla had the best-selling passenger vehicle in the world last year, and in China in March, as the Model Y continued its global dominance over other vehicles.

Musk responded to Farley’s comments by stating:

“This is before Supervised FSD is approved in China. Limiting factor is production output in Shanghai.”

Interestingly, Farley has been one of the most hellbent CEOs in terms of a legacy automaker standpoint to push the EV effort. It did not go according to plan, as Ford took a $19.5 billion charge and retreated from its EV push in late 2025.

Ford cancels all-electric F-150 Lightning, announces $19.5 billion in charges

Instead, Ford is “doubling down on its affordable” EVs and said it would pivot from its previous plans.

Advertisement

Reaction from Tesla fans was pretty much how you would expect. Many said they have lost a lot of respect for Farley after his comments; others believe he is the last CEO anyone should be taking advice on EVs from.

Nevertheless, Farley’s plans are bold and brash; many consider Tesla the most ideal company to replicate EV efforts from. It will be interesting to see if Ford can rebound from this big adjustment, and hopefully, Farley’s plans to replicate efforts from BYD work out the way he hopes.

Continue Reading

Elon Musk

SpaceX wins its first MARS contract but it comes with a catch

NASA awarded SpaceX a $175 million Mars rover contract while the White House proposes cutting the mission.

Published

on

By

NASA just signed a $175.7 million contract with SpaceX to launch a Mars rover that the White House is simultaneously trying to defund. The contract, awarded on April 16, 2026, tasks SpaceX’s Falcon Heavy with launching the European Space Agency’s (ESA) Rosalind Franklin rover from Kennedy Space Center in Florida, no earlier than late 2028. It would mark the first time SpaceX has ever sent a payload to Mars.

Under NASA’s Rosalind Franklin Support and Augmentation project, known as ROSA, the agency is providing braking engines for the rover’s descent stage, radioisotope heater units that use decaying plutonium to keep the rover warm on the Martian surface, additional electronics, and a mass spectrometer instrument, as noted by SpaceNews.

Those nuclear heating units are the reason an American rocket was required at all. U.S. export controls on radioisotope technology mean any payload carrying them must launch on a domestic vehicle, which narrowed the field to SpaceX and United Launch Alliance. Falcon Heavy’s pricing made it the practical choice.

SpaceX is quietly becoming the U.S. Military’s only reliable rocket

Advertisement

Falcon Heavy debuted in February 2018 and has 11 launches to its record. The rocket has not flown since October 2024, when it sent NASA’s Europa Clipper toward Jupiter. The three-core design, built from modified Falcon 9 first stages, gives it the lift capacity needed for deep space planetary missions that a single Falcon 9 cannot reach.

The Rosalind Franklin rover has been sitting in storage in Europe for years. It was originally due to launch in 2022 as a joint mission with Russia, but Russia’s invasion of Ukraine ended that partnership, leaving the rover built but stranded without a launch vehicle or landing hardware. NASA stepped back in through a 2024 agreement with ESA to rescue the mission. The rover is designed to drill up to two meters below the Martian surface in search of evidence of past life, a science objective no previous mission has attempted at that depth.

The contradiction at the center of this story is hard to ignore. The White House’s fiscal year 2027 budget proposal included no funding for ROSA and did not mention the mission at all in the detailed congressional justification document released April 3.

Musk has long argued that reaching Mars is not optional. “We don’t want to be one of those single planet species, we want to be a multi-planet species.” Whether this particular mission survives Washington’s budget fight, the Falcon Heavy contract means SpaceX is now formally on record as the rocket that could get humanity’s next Mars science mission off the ground.

Advertisement

The timing of this contract carries extra weight given that SpaceX filed confidentially with the SEC in early April and is targeting an IPO roadshow in the week of June 8. It would be the largest public offering in history.

Continue Reading

Elon Musk

Tesla Q1 Earnings: What Elon Musk and Co. will answer during the call

Published

on

Credit: Tesla

Tesla (NASDAQ: TSLA) is set to hold its Earnings Call for the first quarter of 2026 on Wednesday, and there are a lot of interesting things that are swirling around in terms of speculation from investors.

With the company’s executives, including CEO Elon Musk, answering a handful of questions that investors submit through the Say platform, fans want to know a lot of things about a lot of things.

These five questions come from Retail Investors, who are normal, everyday shareholders:

  1. When will we have the Optimus v3 reveal? When will Optimus production start, since we ended the Model S and Model X production earlier than mid-year? What’s the expected Optimus production rate exiting this year? What are the initial targeted skills?
  2. What milestones are you targeting for unsupervised FSD and Robotaxi expansion beyond Austin this year, and how will that drive recurring revenue?
  3. How will Hardware 3 cars reach Unsupervised Full Self-Driving?
  4. When do you expect Unsupervised Full Self-Driving to reach customer cars?
  5. When will Robotaxi expand past its current limited rollout?

Additionally, these are currently the three questions that are slated to be answered by Institutional Firms, which also answer a handful of questions during the call:

  1. Now that FSD has been approved in the Netherlands and is expected to launch across Europe this summer, can you discuss your Robotaxi strategy for the region?
  2. What enabled you to finish the AI5 tapeout early and were there any changes to the original vision? Last week, Elon said AI5 will go into Optimus and the Supercomputer, but one month ago said it would go into the Robotaxi. Has AI5 been dropped from the vehicle roadmap?
  3. Given the recent NHTSA incident filings, can you update us on the Robotaxi safety data? If safety validation remains the primary bottleneck, why not deploy thousands of vehicles to accelerate the removal of the safety driver?

The questions range through every current Tesla project, including FSD expansion and Optimus. However, many of the answers we will get will likely be repetitive answers we’ve heard in the past.

This is especially pertinent when the questions about when Unsupervised FSD will reach customer cars: we know Musk will say that it will happen this year. Is Tesla capable of that? Maybe. But a more transparent answer that is more revealing of a true timeline would be appreciated.

Advertisement

Hardware 3 owners are anxiously awaiting the arrival of FSD v14 Lite, which was promised to them last year for a release sometime this year.

The Earnings Call is set to take place on Wednesday at market close.

Continue Reading